ReviewFrontiers in pharmacology2026

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.

Zongze He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.